ValuEngine lowered shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a buy rating to a hold rating in a research note released on Wednesday morning.
Several other brokerages have also recently issued reports on HTGM. Zacks Investment Research cut HTG Molecular Diagnostics from a buy rating to a sell rating in a report on Wednesday, March 28th. HC Wainwright reaffirmed a buy rating and set a $7.00 price objective on shares of HTG Molecular Diagnostics in a report on Friday, March 23rd. Finally, Canaccord Genuity upped their price objective on HTG Molecular Diagnostics from $5.00 to $7.00 and gave the stock a buy rating in a report on Friday, March 23rd.
Shares of HTG Molecular Diagnostics opened at $3.26 on Wednesday, Marketbeat Ratings reports. The company has a market cap of $92.21 million, a P/E ratio of -1.82 and a beta of 1.58. The company has a quick ratio of 9.59, a current ratio of 9.80 and a debt-to-equity ratio of 0.31. HTG Molecular Diagnostics has a 12-month low of $1.59 and a 12-month high of $5.83.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Thursday, May 10th. The medical research company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.04. The business had revenue of $4.16 million during the quarter, compared to the consensus estimate of $5.24 million. HTG Molecular Diagnostics had a negative return on equity of 338.96% and a negative net margin of 105.56%. sell-side analysts expect that HTG Molecular Diagnostics will post -0.66 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. EAM Global Investors LLC purchased a new stake in HTG Molecular Diagnostics during the 1st quarter valued at $684,000. Northern Trust Corp purchased a new stake in HTG Molecular Diagnostics during the 1st quarter valued at $189,000. Stifel Financial Corp purchased a new stake in HTG Molecular Diagnostics during the 1st quarter valued at $343,000. Finally, New York State Common Retirement Fund purchased a new stake in HTG Molecular Diagnostics during the 1st quarter valued at $170,000. Institutional investors own 39.41% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.